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Abstract
Background: Valganciclovir (VGC) is essential for preventing cytomegalovirus infections after transplants in adult
and pediatric patients. In pediatric patients, VGC tablets have to be pulverized so that they can be delivered via
nasogastric tubes. The “simple suspension method” is usually used to suspend tablets in hot water in Japan.
However, the optimal suspension conditions and metering methods for preparing VGC suspensions using the
simple suspension method are unclear. The purpose of this study was to clarify these issues.
Methods: VGC tablets were suspended in water (initial water temperature: 25 °C or 55 °C) using the simple
suspension method. The residual rate of VGC after it had been suspended in hot water was determined using
HPLC. In addition, the suspended solution was passed through 6, 8, and 12 Fr. gavage tubes. The VGC
concentrations of suspensions produced using different preparation methods were also determined using HPLC.
Results: Cracking the surfaces of VGC tablets and suspending them in water at an initial temperature of 55 °C was
effective at dissolving the tablets. The VGC concentration of the suspension remained stable for at least 80 min.
Furthermore, the VGC concentration remained stable for 48 h during cold dark storage. Cracking the surfaces of
VGC tablets could be a more effective metering method than preparing powder from VGC tablets. In addition, little
VGC remained in 6, 8, or 12 Fr. gavage tubes after VGC solution was passed through them.
Conclusion: The amount of VGC should be measured carefully when preparing VGC solutions using the simple
suspension method.
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Background
Cytomegalovirus (CMV) infections are a major cause of
morbidity and mortality among post-transplant patients
[1, 2]. Early CMV infections are associated with an in-
creased risk of acute graft rejection [3]. Some antiviral
drugs can improve graft survival and the outcomes of
transplant patients. The antiviral drugs valganciclovir
(VGC), acyclovir, valaciclovir, and ganciclovir can be
used as prophylaxes against CMV infections. In particu-
lar, VGC is the gold-standard treatment for preventing
and treating CMV infections in adult and pediatric
patients [4, 5].
Medication dosages often have to be adjusted for
pediatric patients. The dose (mg) of VGC given to children
is calculated as follows: 7 × body surface area (m2) × esti-
mated creatinine clearance (mL/min/1.73m2) [4]. VGC is
available in tablet form (450-mg VALIXA® tablets) and as a
dry syrup preparation (VALIXA® 5000-mg dry syrup) in
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: kawasa-y@cc.okayama-u.ac.jp
1Department of Pharmacy, Okayama University Hospital, 2-5-1, Shikata-cho,
Kita-ku, Okayama 700-8558, Japan
Full list of author information is available at the end of the article
Masaoka et al. Journal of Pharmaceutical Health Care and Sciences            (2020) 6:16 
https://doi.org/10.1186/s40780-020-00172-w
Japan. Since VGC is used to treat transplant patients, many
pharmacies only stock the tablet form. Thus, during the
treatment of pediatric patients VGC tablets often have to
be pulverized, before being administered via nasogastric
tubes (6, 8, or 12 Fr.). Our preliminary research revealed
that 9 out of 129 patients (7.0%) that were treated with
VGC at Okayama University Hospital in the last year were
prescribed pulverized VGC powder (produced by crushing
VGC tablets). In particular, pulverized VGC tablets account
for approximately 81% of all VGC prescriptions to pediatric
patients (< 17 years old) at Okayama University Hospital.
VGC has several potential toxicities, e.g., it can be car-
cinogenic and/or teratogenic and can cause azoospermia
[6]. Since pharmacists might be at high risk of inhaling
VGC when they pulverize VGC tablets, it is important
to employ countermeasures to protect them as much as
possible from this. Furthermore, pulverizing tablets
might decrease the VGC concentrations of the resultant
suspensions.
The “simple suspension method” is commonly used to
suspend tablets in hot water (55 °C) in Japan because it
reduces exposure to toxic medicine powders [7]. However,
the use of the simple suspension method to prepare VGC
suspensions for nasogastric tube delivery has not been
investigated in detail. Furthermore, the stability of the
VGC concentrations of such suspensions is unclear.
In the present study, we suspended VGC tablets in hot
water using the simple suspension method and exam-
ined the stability of VGC, as well as the residual rate of
VGC in nasogastric tubes after VGC solution had been
passed through them.
Methods
Reagents and materials
For the HPLC analysis, a VGC reference standard was
purchased from Sigma-Aldrich (MO, USA). Acetonitrile
was obtained from Kanto Chemical Co., Inc. (Tokyo,
Japan). Sodium dihydrogen phosphate dihydrate and
sodium hydrogen phosphate were acquired from Fujifilm
Wako Chemicals Ltd. (Osaka, Japan). For the simple
suspension method, VGC (450-mg VALIXA® tablets)
was provided by Mitsubishi Tanabe Pharma Co. (Osaka,
Japan). The gavage syringes (30 mL) and gavage tubes (6
(length: 40 cm), 8 (length: 80 cm), and 12 French (Fr.)
(length: 120 cm)) were purchased from JMS Co., Ltd.
(Hiroshima, Japan). Twenty-five mM phosphate buffer
was created using sodium dihydrogen phosphate dihy-
drate and sodium hydrogen phosphate.
Examination of the effects of the simple suspension
method on VGC tablets
We prepared VGC solutions under three different condi-
tions. Specifically, an intact VGC tablet (the intact tablet
group), a tablet that had been divided in two (the halved
tablet group), or a tablet in which the film coating had
been cracked (the cracked tablet group) was inserted
into a gavage syringe, and then 20 mL of water (25 °C) or
hot water (55 °C) was taken up into the gavage syringe
containing the tablet. Then, the gavage syringe was left
to rest for 10 or 20 min at room temperature (25 °C).
Stability of VGC after it was suspended in hot water
A VGC tablet whose film coating had been cracked was
inserted into a gavage syringe (30 mL). Twenty milliliters
of hot water (initial temperature: 55 °C) was taken up by
the gavage syringe containing the tablet. Then, the
gavage syringe was left to rest for 20, 35, 50, 65, or 80
min under diffuse light conditions at room temperature
(500 lx, 25 °C). Furthermore, in order to evaluate the
stability of VGC solutions when they are stored for long
periods (1, 24, or 48 h), we examined their stability
under the following three experimental conditions:
under diffuse light storage (500 lx, 25 °C), dark storage
(25 °C), and cold dark storage (4 °C) conditions. Next,
each solution was diluted 1000-fold using 25 mM phos-
phate buffer solution. Samples of the resultant solutions
were injected into an HPLC system.
VGC concentrations produced by different metering
methods
In order to confirm the VGC concentrations produced
by various metering methods, we created three types of
VGC solutions. We postulated that half a VGC tablet
(225 mg) would usually be prescribed to pediatric pa-
tients. Therefore, 1) half a VGC tablet was inserted into
a gavage syringe, and then 20mL of hot water (initial
temperature: 55 °C) was taken up into the gavage syringe
(the half-tablet group); 2) a VGC tablet was pulverized,
half of the pulverized tablet was inserted into a gavage
syringe, and then 20 mL of hot water (55 °C) was taken
up into the gavage syringe (the half-powder group); or 3)
a VGC tablet whose film coating had been cracked was
inserted into a gavage syringe, 20 mL of hot water
(55 °C) was taken up into the gavage syringe, and then
half of the solution (10 mL) was collected (the half-
solution group). Then, the gavage syringe was left to rest
for 20 min at room temperature (25 °C). The resultant
solution was passed through a filter (fine filter F, F162;
Forte Grow Medical Co. Ltd., Tochigi, Japan). Then,
each solution was diluted 1000-fold using 25 mM phos-
phate buffer solution. Samples of the resultant solutions
were injected into an HPLC system.
Amounts of VGC remaining in gavage tubes after VGC
solution was passed through them
A VGC tablet whose film coating had been cracked was
inserted into a gavage syringe. Then, 20 mL of hot water
(initial temperature: 55 °C) was taken up by the gavage
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syringe containing the tablet, before the gavage syringe
was left to rest for 20 min at room temperature (25 °C).
Then, the solution was passed through a 6, 8, or 12 Fr.
gavage tube. Distilled water (20 mL) was then passed
through the gavage tube, and a sample of it was injected
into an HPLC system.
Instruments and conditions
The HPLC analysis was carried out with a Shimadzu
LC-20A system (Shimadzu Co., Kyoto, Japan). The entire
system was controlled using the Shimadzu LC solution
software (Shimadzu Co., Kyoto, Japan). A LiChroCART®
125–4.0 Superspher® 100 RP-18(e) (4 μm) column
(Kanto Chemical Co., Inc., Tokyo, Japan) was used.
Acetonitrile and 25mM phosphate buffer solution (1:9)
was used as the mobile phase at a flow rate of 1.0 mL/
min. The column temperature was kept at 40 °C. The
UV wavelength used was 256 nm. The analysis time was
20min. The injection volume was 25 μL. The amount of
VGC within the VGC solution at each timepoint was
determined using the absolute calibration curve method.
Preparation of the VGC standard solution for the HPLC
Calibration standards were prepared at five concentrations
for the HPLC analysis: 0, 12.5, 25, 50, and 100 μg/mL. The
VGC was dissolved in 25mM phosphate buffer solution.
Statistical analysis
The data are shown as the mean ± standard deviation
(S.D.). The data were analyzed using one-way analysis of
variance (ANOVA) followed by Dunnett’s test or
Tukey’s test. The significance level was set at P < 0.05.
Results
Examination of the effects of the simple suspension
method on VGC tablets
When the tablets were suspended at a water temperature
of 25 °C and then left to rest for 10 min, they remained
solid in all groups. When the tablets were suspended at
a water temperature of 55 °C and then left to rest for 10
min, they also remained solid in all groups. On the other
hand, when the tablets were suspended at a water
temperature of 55 °C and then left to rest for 20 min, the
tablets in the cracked tablet group were completely
suspended in the hot water (Fig. 1).
Stability of VGC after it was suspended in hot water
Figure 2 shows how the residual rate of VGC chan-
ged over time. A residual rate of 100% represented
450 mg of VGC; i.e., the amount of VGC found in
one tablet. The residual rate was 99.9 ± 0.9% after 20
min, 99.4 ± 1.6% after 35 min, 99.9 ± 1.3% after 50 min,
101.8 ± 0.3% after 65 min, and 102.4 ± 0.5% after 80
min. Compared with that seen at 20 min, the residual
rate of VGC did not change significantly until 80 min.
Figure 3 shows the residual rate of VGC from 1 to
48 h under diffuse light storage, dark storage, and
cold dark storage conditions. Under the diffuse light
storage and dark storage conditions, the residual rate
of VGC was significantly decreased at 48 h.
Fig. 1 Effects of the simple suspension method on VGC tablets under various conditions
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VGC concentrations produced by different metering
methods
Figure 4 shows the recovery rates obtained in each
group. The VGC concentration was 85.2 ± 8.1% in the
half-powder group, 105.0 ± 9.6% in the half-tablet group,
and 96.5 ± 1.4% in the half-solution group. The VGC
concentration of the half-solution group was not signifi-
cantly lower than that of the half-powder or half-tablet
group. However, the VGC concentration of the half-
powder group was significantly lower than that of the
half-tablet group [F(2,14) = 7.912, P < 0.01].
Amounts of VGC remaining in gavage tubes after VGC
solution was passed through them
Figure 5 shows the residual rates of VGC in gavage tubes
of different sizes. The residual rate of VGC was 0.07 ±
Fig. 2 Time-dependent changes in the residual rate of VGC. Each point represents the mean ± S.D. of 6 independent experiments
Fig. 3 VGC concentrations produced by different storage conditions. Each point represents the mean ± S.D. of 4–5 independent experiments. *:
Significant difference between the 1-h and 48-h storage conditions (P < 0.05), **: Significant difference between the 1-h and 48-h storage
conditions (P < 0.01)
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0.17% in the 6 Fr. tubes, 0.00 ± 0.04% in the 8 Fr. tubes,
and 0.43 ± 0.82% in the 12 Fr. tubes.
Discussion
In the present study, we demonstrated that suspending
VGC tablets whose surface films had been cracked in
water with a temperature of 55 °C and then allowing the
solution to rest for 20 min was effective at dissolving the
tablets. The VGC in the suspensions produced using
water with a temperature of 55 °C remained stable for
80 min. In addition, little VGC remained in 6, 8, or 12
Fr. gavage tubes after VGC solution had been passed
through them. Moreover, it was suggested that cracking
the surface films of VGC tablets is a more effective
metering method than preparing powder from VGC tab-
lets. Therefore, we consider that preparations containing
the required amount of VGC can be produced using the
simple suspension method. It is important to administer
the required amount of VGC because it increases
patients’ quality of life. Thus, we also consider that the
Fig. 4 VGC concentrations produced by different metering methods. Each point represents the mean ± S.D. of 6 independent experiments. **:
Significant difference between the half-powder group and the half-tablet group (P < 0.01)
Fig. 5 Examination and quantitative determination of residual VGC levels after VGC solution was passed through gavage tubes
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method described in the present study could be useful
for maintaining therapeutic effects in patients that are
prescribed VGC.
A previous study examined the stability of VGC in aque-
ous buffer solutions with pH of 3.8 to 11.5 at 37 °C [8].
They found that the half-life of VGC was markedly pro-
longed in acidic solution. For example, the half-life of
VGC was 220 days in pH 3.81 solution, whereas it was 11
h in pH 7.08 solution. Thus, it is necessary to produce an
acidic solution when VGC tablets are suspended using the
simple suspension method. We previously demonstrated
that a suspension of VGC in water produced using the
simple suspension method had a pH of 6.64.
It is difficult to apply the simple suspension method to
some drugs. In particular, the suspension temperature,
dispersibility, and controlled release can all act as limit-
ing factors. Since lansoprazole can be coagulated by hot
water, the label information issued by the Food and
Drug Administration states that it should be suspended
in water at 25 °C. On the other hand, this is not men-
tioned in the label information given in Japan. While XC
(oral anti-tumor drugs: Xeloda® and cyclophosphamide)
therapy has been developed as a treatment for breast
cancer in recent years [9], cyclophosphamide is known
to be a carcinogen associated with leukemia and bladder
cancer [10]. It decomposes at temperatures of 45 to
53 °C (Japanese Pharmacopoeia), so it cannot be sus-
pended using the simple suspension method. In the
present study, we found that VGC tablets whose surface
films had been cracked remained stable in suspension
for at least 80 min when the suspension was produced
using a water temperature of 55 °C.
As a practical test, we examined the delivery of such
suspensions by gavage tube and found that the suspen-
sions did not block either the tube or injection syringe.
In addition, VGC was hardly detected in gavage tubes
after the solution had been passed through them; i.e.,
the residual rates of VGC in the gavage tubes were
extremely low. Indeed, it was reported that the recovery
rate of ticagrelor, which is a lipophilic compound similar
to VGC, was not affected by the type of tube material
(polyurethane, polyvinylchloride, or silicone) used [11].
As VGC is a water-soluble compound, VGC solutions
can be administered via gavage tubes. Therefore, we
suggest that VGC suspensions created using the simple
suspension method can be used for patients that are
treated with nasogastric tubes.
Regarding bioavailability, the area under the curve
(AUC) value of crushed moxifloxacin tablets in suspen-
sion was slightly, but not significantly, lower than that
seen after treatment with intact moxifloxacin tablets
[12]. However, the AUC of crushed tolvaptan tablets in
suspension was significantly lower than that of intact
tolvaptan tablets [13]. In the current study, the VGC
concentration of the half-solution group was not signifi-
cantly lower than that of the half-tablet group (it was
assumed that half a VGC tablet would usually be
prescribed to pediatric patients). In addition, the VGC
concentration of the half-solution group was not signifi-
cantly lower than that of the half-powder group. However,
the VGC concentration of the half-powder group was
significantly lower (VGC recovery rate: < 90%) than that of
the half-tablet group. Therefore, we consider that some of
the powder from crushed tablets is lost during the prepar-
ation process, which might result in weaker therapeutic
effects. Furthermore, under the diffuse light storage and
dark storage conditions, the residual rate of VGC was
significantly decreased at 48 h. It is recommended that
tablets that are dissolved using the simple suspension
method should be stored in cold dark conditions.
Conclusions
Preparing VGC suspensions might protect nursing staff
from the adverse effects of aerosolized VGC; reduce the
potential loss of the drug during its preparation; and prevent
tube-clogging problems, which can arise when insufficiently
crushed tablets or a powder that is too thick is administered.
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